Navigation Links
TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
Date:12/10/2007

of patients with CLL and Cephalon expects a review decision from FDA by the end of March 2008. FDA granted orphan drug status for TREANDA for CLL in August 2007, which would entitle Cephalon to a seven-year period of marketing exclusivity for this indication in the United States, if the product is approved.

TREANDA is also being studied for the treatment of patients with indolent non-Hodgkin's lymphoma (NHL) whose disease has progressed during or following treatment with rituximab. The detailed results of this Phase 3 study also were presented during the ASH annual meeting. In addition, Cephalon has studied TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. Cephalon plans to submit an NDA for TREANDA by the end of 2007 as a single agent for the treatment of patients with indolent NHL whose disease has progressed during or following treatment with rituximab.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited, under the tradename RIBOMUSTIN(R). In Germany, RIBOMUSTIN is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asian countries.

About Cephalon Oncology

Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. In addition to TREANDA, the Cephalon Oncology therapeutic portfolio in the United States includes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United Sta
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
7. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
8. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... from the Company,s Board of Directors in order to ... of Impax in 1995 and served as the Company,s ... April 2014. Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO ... Chief Executive Officer stated, "We wish to thank Larry ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Rochester Medical Corporation (NASDAQ: ROCM ) will announce ... 2012.  The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). ... be accessed at Rochester Medical,s website at www.rocm.com .  ...
...   Hospira, Inc. (NYSE: HSP ), the ... announced enrollment of the first patient in a Phase III ... III program, which follows a successful Phase I trial that ... EPO and the reference product, Amgen,s Epogen ® in ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2012 Earnings Conference Call, Wednesday, January 25, 2012 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 3
(Date:7/5/2015)... ... 2015 , ... Security Life Insurance Company of America, a ... of PrimeStar Individual Dental Insurance. Beginning now, enhancements include the expansion of our ... (MAC) and usual, customary and reasonable (UCR). , Whether consumers are looking ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women’s Excellence in Wellness, ... Lake Orion location. The special consists of 2 months of unlimited classes for just ... Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... ... 2015 , ... Chronic Neck Pain. Neck pain is no small ... the neck. Another 19% suffer from head, migraine, or facial pain, in some cases ... of American workers must deal with neck pain. Strategies for mitigating neck ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon ... 2nd creating a buzz of media attention. In an effort to spread the ... Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress and ...
(Date:7/3/2015)... ... , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod ... . To be held from March 4th - 6th, the 2016 (a previous announcement ... Dallas. , Designed to take participants from the basic training and fundamentals of nasal ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... smoking greatly increases the risk that a blood vessel ... called an aneurysm which could be life-threatening if ... Stroke Association,s International Stroke Conference 2010. Researchers reported on ... project, a multinational collaboration funded by the National Institutes ...
... , , ... ... , , ... ...
... first one, number of teeth in first year , FRIDAY, ... in the first year of life have been identified by ... of 6,000 people in Finland and Britain who took part ... until adulthood. The scientists pinpointed five genes associated with the ...
... ... allows point-of-care workers to improve workflow and patient care. , ... (PRWEB) February 26, 2010 ... partnership with Voalt , a leading developer of innovative point-of-care communications software ...
... ... patients and asbestos exposure victims who are interested in learning more about clinical trials ... ... provide comprehensive resources for mesothelioma patients and their loved ones, including information about ...
... ... the public to spend two moonlit evenings basking in blissful meditations and looking at ... ... opportunity to explore life,s most fascinating questions at a most unexpected place, Tampa,s USF ...
Cached Medicine News:Health News:Smoking significantly increases risk of aneurysm in people with certain genes 2Health News:Smoking significantly increases risk of aneurysm in people with certain genes 3Health News:Landauer, Inc. Declares Regular Cash Dividend 2Health News:Genes Behind Tooth Development Discovered 2Health News:Connexall Announces Partnership with Voalt 2Health News:Connexall Announces Partnership with Voalt 3Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 2Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 3Health News:Explore, Love, Happiness, Life Purpose, and Destiny with World Renowned Yogi and Mystic, Sadhguru 2
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: